Healthcare, biotechnology & medical AI Product
IDx-DR received De Novo authorization for automated retinal screening
IDx-DR analyzes retinal images to detect more than mild diabetic retinopathy in the population specified by the FDA. The 2018 decision covers the software in combination with the Topcon NW400 retinal camera. [1]
- Release status
- U.S. FDA De Novo granted April 11, 2018, under DEN180001. [1]
What it does
On April 11, 2018, the FDA granted IDx-DR a De Novo request and classified its device type as Class II retinal diagnostic software. [1]
Why it matters
This filing establishes an autonomous screening role for the specified retinal finding. The camera and intended use are part of the scope of the decision. [1]
Who it’s for
The labeled use concerns healthcare providers screening adults with diabetes who have no prior diagnosis of diabetic retinopathy. [1]
Key dates
- FDA grants the IDx-DR De Novo request [1]
Where it fits
The authorized workflow pairs the analysis software with retinal images acquired on the named Topcon model. [1]
Limits and trade-offs
The cited authorization is specific to the named configuration and retinal finding. [1]
Sources and verification
Catalog evidence checked How we verify records
Related profiles
Healthcare, biotechnology & medical AI
Sleep Analysis Module (SAM)
Neurotronics (Nihon Kohden)
The module estimates sleep time from a signal captured during its intended sleep-testing workflow.
Healthcare, biotechnology & medical AI
Heartvue.Proton
Heartvue.ai
It is software for analyzing cardiac MRI images within its documented intended-use scope.
Healthcare, biotechnology & medical AI
ThinkSono Guidance
ThinkSono
Provides guidance during acquisition of lower-extremity compression ultrasound images for review by healthcare professionals.